Huang, Wei-Ching
Chuang, Chi-Fen
Huang, Yung-Tsang
Chung, I-Che
Chen, Mao-Lin
Chuang, Tung-Yueh
Yang, Xiu-Li
Chou, Yu-Yau
Liu, Chih-Hsin
Chen, Nai-Yu
Chen, Chun-Jen
Yuan, Ta-Tung
Article History
Received: 7 November 2022
Accepted: 27 October 2023
First Online: 14 November 2023
Declarations
:
: Human peripheral blood was collected from healthy volunteers who gave written consent with specific approval from the Institutional Review Board of the Development Center of Biotechnology (DCB) (DCB-IRB-110012). Animal experiments were carried out in strict accordance with the approved protocols from the Institutional Animal Care and Use Committee (IACUC) of TFBS Bioscience (IACUC No. TFBS2020-007 and TFBS2023-003).
: Not applicable.
: TTY is advisor at HuniLife Biotechnology which is a clinical stage company developing ENO1 antibodies as therapeutics for cancers, inflammatory disorders, and fibrotic diseases. TTY, WCH, ICC, CFC, MLC, and YTH are inventors on pending patent application for the use of ENO1 antagonists as anti-fibrotic agents. The authors declare that they have no competing interests.